Cite

HARVARD Citation

    Zhang, H. et al. (2022). A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. Leukemia & lymphoma. 63 (6), pp. 1418-1427. [Online]. 
  
Back to record